ImmunoCellular Therapeutics AI Stock Analysis
ImmunoCellular Therapeutics (IMUC) AI Stock Analysis
ImmunoCellular Therapeutics
(Other OTC:IMUC)
No summary available
ImmunoCellular Therapeutics (IMUC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $19.99M
- Dividend Yield
- ―
- Average Volume (3M)
- 3,218
- Price to Earnings (P/E)
- -10.4
- Beta (1Y)
- 0.27
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ImmunoCellular Therapeutics Business Overview & Revenue Model
Company Description
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United S...
ImmunoCellular Therapeutics Risk Analysis
ImmunoCellular Therapeutics disclosed 36 risk factors in its most recent earnings report. ImmunoCellular Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksImmunoCellular Therapeutics Peers Comparison
Overall Rating
BOLT47Neutral
XBIO47Neutral
INAB41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $14.73M | -0.40 | -154.11% | ― | -51.28% | 32.80% | |
| 47Neutral | $3.77M | -1.00 | -58.96% | ― | 3.50% | 22.76% | |
| 41Neutral | $8.86M | -0.69 | -93.66% | ― | ― | 81.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMUC | Immunocellular Therapeutics, Ltd. | 0.16 | -0.02 | -12.29% | |
| XBIO | Xenetic Biosciences, Inc. | 1.61 | -0.70 | -30.30% | |
| INAB | In8bio, Inc. | 0.82 | -0.77 | -48.43% | |
| BOLT | Bolt Biotherapeutics, Inc. | 5.65 | 0.85 | 17.71% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
